Pioneering UK Clinical Research Center Partners with OmniComm Systems
Fort Lauderdale, FL, April 14, 2014 –- OmniComm Systems, Inc. (OTCQB: OMCM), a leading global provider of clinical data management solutions for clinical trials, announced the signing of a five year agreement for its Promasys investigator initiated trials (IITs) technology with Surrey Clinical Research Centre (Surrey CRC) at the University of Surrey, a UK based research center focused on the design and execution of Phase I and IIa trials in sleep, psychopharmacology, oncology, immunology and vaccines.
After a thorough evaluation process of various commercially available technologies, Surrey CRC selected Promasys technology to manage its clinical research activities. Promasys ranked highest across all categories including ease of use, fast study build, data quality and integrity and volunteer recruitment. Promasys’ versatility through its mobile technology and overall functionality, as well as its lower total cost-of-ownership, was also a significant factor in the decision.
“We look forward to working with OmniComm Promasys,” states Carol Stillwell, head of data management, Surrey CRC. “Having worked with several commercial technologies over the past couple of years, we were impressed by the ease of operation of the Promasys system, and with the backing of an established company such as OmniComm feel that Promasys will go from strength to strength.”
Promasys will be used by Surrey CRC to support both in-house and external studies including investigator initiated trials (IITs), National Health Service (NHS) studies, and industry sponsored trials.
“We are extremely proud to have Surrey CRC as our first Promasys customer in the UK,” says Wolf Ondracek, senior vice president of Academic and Asian Markets and managing director, OmniComm Promasys. “Promasys software originates from an academic environment at a top class clinical pharmacology research centre very similar to Surrey CRC. So it is a very natural fit, and it will be a pleasure for us to work closely with Surrey CRC and support them in getting the most out of our software solution.”
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
OmniComm and TrialMaster are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.